Health Technology Review No. 12, August 1995. Hematopoietic Stem-CellTransplantation in Multiple Myeloma

摘要

Current conventional chemotherapeutic regimens have failed to effect either cureor long-term survival in patients with multiple myeloma. The feasibility of high-dose chemotherapy (HDCT) with hematopoietic stem-call support in multiple myeloma has been documented in hundreds of patients, and a number of randomized clinical trials comparing such treatment with conventional therapies are planned or ongoing. The available data from some trials suggest that HDCT regimens are associated with both improved responses and survival; however, the limited data from randomized trials are conflicting, and no published study reveals stable plateaus of complete remission or survival curves. Further study is required to determine the role of stem-cell transplantation in multiple myeloma.